Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

Purpose: This phase II study evaluated the impact of adding ribociclib to maintenance endocrine therapy (ET) treatment of physicians’ choice following the first palliative chemotherapy in pre- and post-menopausal women with hormone receptor positive (HR+)/human epidermal growth factor 2 negative (HE...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, Nader Hirmas, Kristina Lübbe, Mark-Oliver Zahn, Marcus Schmidt, Carsten Denkert, Ralf Lorenz, Volkmar Müller, Dirk-Michael Zahm, Christoph Mundhenke, Stefan Bauer, Marc Thill, Peter Seropian, Natalie Filmann, Sibylle Loibl
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2023-12-01
سلاسل:	Breast
الموضوعات:	Advanced breast cancer Metastatic breast cancer Hormone receptor positive HER2 negative Ribociclib AMICA
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S0960977623005428
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!